Mycenax Biotech (ROCO:4726) Other Current Assets: NT$280.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4726 Mycenax Biotech Inc ROCO:4726
42 GF Score
Price NT$24.35
GF Value NT$48.73
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Mycenax Biotech Other Current Assets?

Mycenax Biotech ROCO:4726 -0.41% 42 Other Current Assets is NT$280.4 Mil as of Mar. 2026. GuruFocus rates ROCO:4726 with a GF Score™ of 42/100 and a GF Value™ of NT$48.73 (Possible Value Trap). The stock has 5 warning signs investors should review.

Mycenax Biotech's other current assets for the quarter that ended in Mar. 2026 was NT$280.4 Mil.

Mycenax Biotech's quarterly other current assets declined from Sep. 2025 (NT$289.5 Mil) to Dec. 2025 (NT$278.4 Mil) but then increased from Dec. 2025 (NT$278.4 Mil) to Mar. 2026 (NT$280.4Mil).

Mycenax Biotech's annual other current assets declined from Dec. 2023 (NT$253.6 Mil) to Dec. 2024 (NT$244.9 Mil) increased from Dec. 2024 (NT$244.9 Mil) to Dec. 2025 (NT$278.4 Mil).


Mycenax Biotech Other Current Assets Related Terms


Mycenax Biotech Other Current Assets Historical Data

* Premium members only.

The historical data trend for Mycenax Biotech's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mycenax Biotech Other Current Assets Chart

Mycenax Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.51 251.97 253.58 244.90 278.39

Mycenax Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 283.53 256.93 289.45 278.39 280.36
ROCO:4726
42GF Score
Mycenax Biotech Inc ROCO:4726
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mycenax Biotech Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of NT$280.4 Mil mean?
Mycenax Biotech (ROCO:4726) has a Other Current Assets of NT$280.4 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Mycenax Biotech.
Is Mycenax Biotech's Other Current Assets too high?
Mycenax Biotech's current Other Current Assets is NT$280.4 Mil. Overall, Mycenax Biotech has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's Other Current Assets compare to VRTX and REGN?
Mycenax Biotech's Other Current Assets of NT$280.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Mycenax Biotech. Mycenax Biotech's current Other Current Assets is NT$280.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.73, compared to a current price of NT$24.35 — trading 50% below its estimated fair value. The current Other Current Assets is NT$280.4 Mil. Mycenax Biotech's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current Other Current Assets is NT$280.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?

Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued. The current stock price of NT$24.35 is trading 50% below its estimated GF Value™ of NT$48.73. GuruFocus considers Mycenax Biotech to be Possible Value Trap.

Key valuation signals for ROCO:4726:

  • Other Current Assets: NT$280.4 Mil
  • GF Value™: NT$48.73 vs. price of NT$24.35 (50% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mycenax Biotech Business Description

Address No. 66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
42GF Score

Get the complete analysis for ROCO:4726

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.35
Price
NT$48.73
GF Value